Larimar Therapeutics, Inc. (LRMR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
Key ratios (FY2025)
-212.2%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Operating Income | -$172.50M | -$90.89M | -$41.76M | -$36.53M | -$50.47M | -$42.80M | -$23.21M | -$61.12M | -$53.00M | -$58.23M |
| Net Income | -$165.67M | -$80.60M | -$36.95M | -$35.35M | -$50.64M | -$42.48M | -$23.13M | -$61.37M | -$52.03M | -$57.88M |
| EPS (Diluted) | — | $-1.32 | $-0.84 | $-1.37 | $-2.95 | $-3.57 | — | — | — | — |
| Total Assets | $145.84M | $200.22M | $95.94M | $126.41M | $78.67M | $104.69M | $5.20M | $121.76M | $105.51M | $131.62M |
| Total Liabilities | $67.76M | $28.41M | $14.21M | $15.50M | $14.25M | $14.99M | $5.89M | $28.49M | $27.29M | $9.89M |
| Shareholders' Equity | $78.08M | $171.81M | $81.72M | $110.90M | $64.41M | $89.69M | -$694.0K | $2.91M | $78.22M | $121.73M |
| Cash & Equivalents | $85.41M | $33.22M | $26.75M | $26.82M | $70.10M | $68.15M | $1.01M | $49.33M | $40.78M | $32.35M |
| Operating Cash Flow | -$113.20M | -$70.76M | -$33.46M | -$27.57M | -$42.10M | -$42.20M | -$22.70M | -$51.49M | -$43.78M | -$51.98M |
| Capital Expenditures | $91.0K | $515.0K | $164.0K | $100.0K | $333.0K | $62.0K | $83.0K | $108.0K | $55.0K | $660.0K |
| Shares Outstanding | 83.09M | 63.82M | 43.91M | 43.27M | 17.71M | 15.37M | 6.09M | 37.29M | 27.49M | 27.33M |